Lancet Series 2021: Obesity in China
2021
This Lancet Series reviews the rise of obesity in China, wherein more than half the adult population are now living with overweight or obesity. While the prevalence of obesity has been well-documented in high-income countries, the growing trends in low- and middle-income countries have been less publicized. Moreover, given that much of the current literature on first-line treatment of overweight and obesity are based on clinical trials with poor racial and ethnic diversity, questions remain regarding the potential efficacy for non-White populations. In China, rapid economic growth, globalization, and urbanization have been tied with the rise in overweight and obesity. Against this backdrop, the papers in this Series fill a niche; articles in this Series focus on the epidemiology and determinants of obesity in China; its clinical management and treatment; and current Chinese health policies.
Series papers include:
- Epidemiology and Determinants of Obesity in China
- Clinical Management and Treatment of Obesity in China
- Health Policy and Public Health Implications of Obesity in China
The Series papers are also accompanied by an infographic summarizing key messages, a profile, and an editorial. The Series papers are also available in Mandarin Chinese to maximize the visibility and impact of the findings.
Lancet Series 2021: Obesity in China
Source:
Obesity in China. The Lancet Diabetes & Endocrinology 2021. https://www.thelancet.com/series/obesity-in-china.